Showing 1 – 20 of 698
Best Match | Most Recent | Oldest |
  • Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial

    Abstract Full Text
    online first
    JAMA Oncol. 2016; doi: 10.1001/jamaoncol.2016.3358

    This secondary analysis of the TRIO-013 phase 3 randomized clinical trial attempts to determine if gastric acid suppressants such as proton pump inhibitors may impair capecitabine efficacy.

  • JAMA Oncology

    Figure: Overall Survival

    Kaplan-Meier curves show overall survival betweens patients treated with or without proton pump inhibitors (PPIs) and (A) capecitabine and oxaliplatin (CapeOx) alone or (B) CapeOx with lapatinib.
  • JAMA Oncology

    Figure: Progression-Free Survival

    Kaplan-Meier curves show progression-free survival betweens patients treated with or without proton pump inhibitors (PPIs) and (A) capecitabine and oxaliplatin (CapeOx) alone or (B) CapeOx with lapatinib.
  • Drug-Drug Interactions With Oral Antineoplastic Agents

    Abstract Full Text
    online first
    JAMA Oncol. 2016; doi: 10.1001/jamaoncol.2016.3323

    This Viewpoint addresses the increasing incidence of drug-drug interactions with personalized cancer treatment drugs.

  • Patterns of Prescription Drug Use Before and After Fragility Fracture

    Abstract Full Text
    JAMA Intern Med. 2016; 176(10):1531-1538. doi: 10.1001/jamainternmed.2016.4814

    This pharmacoepidemiology study uses Medicare Part D data to describe changes in use of prescription drugs associated with an increase in fracture risk before and after fragility fractures.

  • National Practice Patterns of Antireflux Medication for Chronic Rhinosinusitis

    Abstract Full Text
    JAMA Otolaryngol Head Neck Surg. 2016; 142(7):627-633. doi: 10.1001/jamaoto.2016.0937

    This cross-sectional analysis uses data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey to determine whether chronic rhinosinusitis is associated with administration of antireflux medications.

  • Sticky Palms Following Use of Proton-Pump Inhibitors

    Abstract Full Text
    JAMA Dermatol. 2016; 152(6):722-723. doi: 10.1001/jamadermatol.2016.0094

    This case report describes 2 patients with sticky palms as an adverse effect of proton-pump inhibitors.

  • Estimation of Potential Savings Through Therapeutic Substitution

    Abstract Full Text
    JAMA Intern Med. 2016; 176(6):769-775. doi: 10.1001/jamainternmed.2016.1704

    This cross-sectional study estimates potential savings through therapeutic substitution in terms of both overall and out-of-pocket expenditures of branded drugs when a generic in the same class with the same indication was available.

  • Effect of Detecting and Isolating Clostridium difficile Carriers at Hospital Admission on the Incidence of C difficile Infections: A Quasi-Experimental Controlled Study

    Abstract Full Text
    JAMA Intern Med. 2016; 176(6):796-804. doi: 10.1001/jamainternmed.2016.0177

    This quasi-experimental controlled study investigates the effect of detecting and isolating Clostridium difficile asymptomatic carriers at hospital admission on the incidence of health care–associated C difficile infection in a Canadian acute care facility.

  • Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes

    Abstract Full Text
    free access
    JAMA. 2016; 315(19):2104-2112. doi: 10.1001/jama.2016.5657

    This study characterizes the histologic features of esophageal inflammation in patients with acute gastroesophageal reflux disease during and after discontinuation of proton pump inhibitor treatment.

  • JAMA

    Figure: Study Design

    LA indicates Los Angeles; GERD-HRQL, Gastroesophageal Reflux Disease Health-Related Quality of Life; PPI, proton pump inhibitor.
  • JAMA

    Figure: Representative Images of the Distal Esophagus From a Single Patient at Baseline and at 1 Week and 2 Weeks After Discontinuation of PPI Therapy

    LA indicates Los Angeles; PPI, proton pump inhibitor. At baseline, HD-WLE showed an irregular tongue of columnar mucosa (Barrett esophagus) in the 12 o’clock position, but no esophagitis. At day 9, HD-WLE showed long linear mucosal breaks (4 and 6 o’clock positions) extending up the esophagus from the gastroesophageal junction (LA grade B esophagitis). At day 16, HD-WLE showed long mucosal breaks continuous between the tops of mucosal folds (LA grade C esophagitis). CLE revealed fluorescein within bright intraepithelial capillaries (yellow arrowheads), with fluorescein that leaked from blood vessels into intercellular spaces surrounding individual cells, creating a reticular appearance characteristic of squamous epithelium. CLE measurements revealed widened intercellular spaces with increased intercellular fluorescein at days 9 and 16. In the photomicrographs at day 9 and 16, black arrowheads indicate some of the numerous intraepithelial lymphocytes. Note the prominent lymphocytosis, basal cell hyperplasia, and papillary elongation at 2 weeks after discontinuation of PPI therapy. All photomicrographs are H&E stains, original magnification ×20. All images were modified in Photoshop to remove patient identification data, and to enhance clarity. Any adjustments in contrast, color balance, brightness or sharpness were applied to the entire image.
  • Inappropriate Prescription of Proton Pump Inhibitors in the Setting of Steroid Use: A Teachable Moment

    Abstract Full Text
    JAMA Intern Med. 2016; 176(5):594-595. doi: 10.1001/jamainternmed.2016.0603

    This case of a woman in her 60s presenting with ear fullness and asymetric hearing loss is a reminder to carefully consider indications for treatment using proton pump inhibitors in the setting of steroid use.

  • Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis

    Abstract Full Text
    JAMA Neurol. 2016; 73(4):410-416. doi: 10.1001/jamaneurol.2015.4791

    This cohort study examines the association between the use of proton pump inhibitors and the risk of incident dementia in an elderly German population.

  • Do Proton Pump Inhibitors Increase the Risk of Dementia?

    Abstract Full Text
    JAMA Neurol. 2016; 73(4):379-381. doi: 10.1001/jamaneurol.2015.4931
  • Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011

    Abstract Full Text
    JAMA Intern Med. 2016; 176(4):473-482. doi: 10.1001/jamainternmed.2015.8581

    In a nationally representative sample of older adults, this study characterizes changes in the prevalence of medication use and quantifies the frequency and types of potential major drug-drug interactions.

  • Adverse Effects Associated With Proton Pump Inhibitors

    Abstract Full Text
    JAMA Intern Med. 2016; 176(2):172-174. doi: 10.1001/jamainternmed.2015.7927
  • Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease

    Abstract Full Text
    JAMA Intern Med. 2016; 176(2):238-246. doi: 10.1001/jamainternmed.2015.7193

    This population-based cohort study quantifies the association between proton pump inhibitor use and incident chronic kidney disease among participants in the Atherosclerosis Risk in Communities study.